Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer

BACKGROUND. Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed cell death‐1 protein ligand (PD‐L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non‐small...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Chae, Young Kwang, Davis, Andrew A., Agte, Sarita, Pan, Alan, Simon, Nicholas I., Iams, Wade T., Cruz, Marcelo R., Tamragouri, Keerthi, Rhee, Kyunghoon, Mohindra, Nisha, Villaflor, Victoria, Park, Wungki, Lopes, Gilberto, Giles, Francis J.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2019
主題:
Immuno‐Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656496/
https://ncbi.nlm.nih.gov/pubmed/30867242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0433
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料